Esperion Therapeutics Inc... (ESPR)
| Bid | 1.73 |
| Market Cap | 343.27M |
| Revenue (ttm) | 344.13M |
| Net Income (ttm) | -53.58M |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -6.2 |
| Forward PE | -18.06 |
| Analyst | Buy |
| Ask | 1.74 |
| Volume | 4,142,263 |
| Avg. Volume (20D) | 4,951,791.7 |
| Open | 1.71 |
| Previous Close | 1.69 |
| Day's Range | 1.67 - 1.75 |
| 52-Week Range | 1.47 - 3.94 |
| Beta | 1.04 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...
Analyst Forecast
According to 7 analyst ratings, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 130.55% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call TranscriptEsperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and ...
